Aura Biosciences, Inc. (AURA) stock
Close on Nov 11, 2026Market cap $789.19MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $789.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.75
- Dividend yield
- –
- Free cash flow yield
- -13.90%
Fundamentals
- Net income
- -$136.95M
- EPS, diluted
- -$1.65
- Free cash flow
- -$109.68M
- Book value per share
- $2.59
- Diluted shares
- 111M
Trading
- Next earnings
- Mar 29, 2027 (estimated, before the open)
- Previous close
- $7.65
- Open
- $7.71
- Day's range
- $7.31 – $7.71
- Volume
- 648,547
- Average volume (20 days)
- 791,275
- Index membership
- Russell 2000 (since Dec 2021), Russell 3000 (since Nov 2021)
- Beta (5 years)
- 1.37
- 52-week range
- $4.73 – $9.54
- RSI (14 days)
- 67.8
- Volatility (1 year)
- 58.1%
- Relative volume
- 0.83×
- WACC
- 11.7%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AURA | S&P 500 | Difference | AURA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +16.4% | -2.4% | +18.8 pts | ||
| 3 months | -5.3% | -1.2% | −4.2 pts | ||
| Year to date | +39.6% | +12.3% | +27.3 pts | ||
| 1 year | +34.5% | +12.4% | +22.0 pts | ||
| 3 years | -1.0% | +78.8% | −79.9 pts | -0.3% | +21.4% |
| 5 years | -55.9% | +75.2% | −131.1 pts | -15.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aura Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Aura Biosciences
Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted therapies for solid tumors to eliminate cancer cells while preserving organ function. The company focuses on virus-like drug conjugates, utilizing modified viral capsids linked to light-activated agents that induce acute necrosis and activate an antitumor immune response. Its primary product candidate is belzupacap sarotalocan (bel-sar), which is under development for ocular oncology indications, including early choroidal melanoma, choroidal metastases, and ocular surface cancers, as well as urologic oncology indications like non-muscle invasive bladder cancer. Because its product candidates remain in clinical investigation, the company does not currently sell commercial products; its intended end users are cancer patients and specialized medical practitioners.
Company profile, executives and historyAura Biosciences stock: common questions
What is Aura Biosciences's stock price?
AURA closed at $7.61 on Nov 11, 2026, down 0.52% on the day. Over the past 52 weeks it traded between $4.73 and $9.54.
What is Aura Biosciences's market cap?
Aura Biosciences was worth $789.19M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AURA's P/E ratio?
Aura Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.65), so it has no meaningful P/E ratio.
Does Aura Biosciences pay a dividend?
No. Aura Biosciences has not paid a cash dividend over the last twelve months.
When does Aura Biosciences report earnings next?
Aura Biosciences is expected to report Q4 FY2026 results on Mar 29, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AURA stock performed over the past year?
Including dividends, AURA returned +34.5% over the past year, against +12.4% for the S&P 500.
How many AURA shares are sold short?
10M shares were sold short at the latest FINRA report, 10.89% of the float, or 13.7 days of average trading volume.
Who are Aura Biosciences's competitors?
Companies most similar to Aura Biosciences by business, industry and size include CADL, CRIS, INTS, CERO, CLDI.
See a number that looks wrong?